Cargando…
Advances in Cutaneous Squamous Cell Carcinoma Management
SIMPLE SUMMARY: Cutaneous squamous cell carcinoma (cSCC) is an increasingly prevalent and morbid cancer worldwide. Management of this cancer has changed significantly in the last decade through improved risk stratification and new therapies offering patients with locally advanced and metastatic dise...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367549/ https://www.ncbi.nlm.nih.gov/pubmed/35954316 http://dx.doi.org/10.3390/cancers14153653 |
_version_ | 1784765841239179264 |
---|---|
author | Burns, Carrick Kubicki, Shelby Nguyen, Quoc-Bao Aboul-Fettouh, Nader Wilmas, Kelly M. Chen, Olivia M. Doan, Hung Quoc Silapunt, Sirunya Migden, Michael R. |
author_facet | Burns, Carrick Kubicki, Shelby Nguyen, Quoc-Bao Aboul-Fettouh, Nader Wilmas, Kelly M. Chen, Olivia M. Doan, Hung Quoc Silapunt, Sirunya Migden, Michael R. |
author_sort | Burns, Carrick |
collection | PubMed |
description | SIMPLE SUMMARY: Cutaneous squamous cell carcinoma (cSCC) is an increasingly prevalent and morbid cancer worldwide. Management of this cancer has changed significantly in the last decade through improved risk stratification and new therapies offering patients with locally advanced and metastatic disease more effective, less toxic, and more durable treatment options. Ongoing clinical trials are assessing new therapeutic options as well as optimizing existing regimens in efforts to better manage this cancer. The recent developments highlight the need for multidisciplinary care, especially for those with locally advanced and metastatic disease. ABSTRACT: cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future. |
format | Online Article Text |
id | pubmed-9367549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93675492022-08-12 Advances in Cutaneous Squamous Cell Carcinoma Management Burns, Carrick Kubicki, Shelby Nguyen, Quoc-Bao Aboul-Fettouh, Nader Wilmas, Kelly M. Chen, Olivia M. Doan, Hung Quoc Silapunt, Sirunya Migden, Michael R. Cancers (Basel) Review SIMPLE SUMMARY: Cutaneous squamous cell carcinoma (cSCC) is an increasingly prevalent and morbid cancer worldwide. Management of this cancer has changed significantly in the last decade through improved risk stratification and new therapies offering patients with locally advanced and metastatic disease more effective, less toxic, and more durable treatment options. Ongoing clinical trials are assessing new therapeutic options as well as optimizing existing regimens in efforts to better manage this cancer. The recent developments highlight the need for multidisciplinary care, especially for those with locally advanced and metastatic disease. ABSTRACT: cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future. MDPI 2022-07-27 /pmc/articles/PMC9367549/ /pubmed/35954316 http://dx.doi.org/10.3390/cancers14153653 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Burns, Carrick Kubicki, Shelby Nguyen, Quoc-Bao Aboul-Fettouh, Nader Wilmas, Kelly M. Chen, Olivia M. Doan, Hung Quoc Silapunt, Sirunya Migden, Michael R. Advances in Cutaneous Squamous Cell Carcinoma Management |
title | Advances in Cutaneous Squamous Cell Carcinoma Management |
title_full | Advances in Cutaneous Squamous Cell Carcinoma Management |
title_fullStr | Advances in Cutaneous Squamous Cell Carcinoma Management |
title_full_unstemmed | Advances in Cutaneous Squamous Cell Carcinoma Management |
title_short | Advances in Cutaneous Squamous Cell Carcinoma Management |
title_sort | advances in cutaneous squamous cell carcinoma management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367549/ https://www.ncbi.nlm.nih.gov/pubmed/35954316 http://dx.doi.org/10.3390/cancers14153653 |
work_keys_str_mv | AT burnscarrick advancesincutaneoussquamouscellcarcinomamanagement AT kubickishelby advancesincutaneoussquamouscellcarcinomamanagement AT nguyenquocbao advancesincutaneoussquamouscellcarcinomamanagement AT aboulfettouhnader advancesincutaneoussquamouscellcarcinomamanagement AT wilmaskellym advancesincutaneoussquamouscellcarcinomamanagement AT chenoliviam advancesincutaneoussquamouscellcarcinomamanagement AT doanhungquoc advancesincutaneoussquamouscellcarcinomamanagement AT silapuntsirunya advancesincutaneoussquamouscellcarcinomamanagement AT migdenmichaelr advancesincutaneoussquamouscellcarcinomamanagement |